Table 2 Results from animal model-based experiments with HU-331
Mouse model | Cancer/tumor type | Dose and route of administration | Effect | Reference |
|---|---|---|---|---|
Nude mice | HT-29 human colon cancer | 5 mg/kg 3x/week, subcutaneous and intraperitoneal 5 mg/kg 3x/week, subcutaneous and intratumoral 2.5 mg/kg, intraperitoneal | Significant tumor reduction with both routes Subcutaneous has faster response than intratumoral Less effective than 5 mg/kg | Kogan et al. (2004) |
Nude mice | HT-29 human colon cancer cells | 15 mg/kg/week, subcutaneous | Decrease in tumor vascularization | Kogan et al. (2006) |
Sabra mice | 7.5 mg/kg/week | No major toxicities; mice gained weight | Kogan et al. (2007a) | |
Nude mice | HT-29 human colon cancer cells | 5 mg/kg, 3x/week | Tumor shrinkage, weight gain, no change in ejection fraction, and no increase in cTnT | |
SCID-NOD mice | Raji human B-cell lymphoma | 15 mg/kg/week | Tumor shrinkage, weight gain, no increase in cTnT, nonsignificant effect on white blood cells, no evidence of cardiotoxicity |